Aptose Biosciences Reports Q1 2026 Results and Acquisition Update
Aptose Biosciences Inc. announced its financial results for the first quarter ended March 31, 2026, alongside significant corporate updates regarding its acquisition by Hanmi Pharmaceutical and clinical trial progress. The closing of the acquisition arrangement has been delayed due to pending Korean regulatory approvals, though both parties target completion in May 2026. Under the agreement, Aptose shareholders are set to receive C$2.41 per share, representing a 28% premium. Clinically, Aptose highlighted robust data from its Phase 1/2 TUSCANY trial, which evaluates tuspetinib in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML). This triplet therapy aims to serve patients ineligible for induction chemotherapy, including those with adverse mutation profiles like TP53. Updated safety and efficacy data, including new findings from the 160 mg dose level, will be presented orally at the upcoming European Hematology Association (EHA) Congress in Stockholm this June. The company continues to position tuspetinib as a well-tolerated, broadly active frontline therapy for diverse AML populations.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection